fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Rheumacensus experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements – UCB

Written by | 4 Dec 2023

As part of its longstanding commitment to patients in rheumatology, UCB, a global biopharmaceutical company, is sponsoring an expert-led, multi-stakeholder programme called Rheumacensus. The programme aims to identify… read more.

AbbVie showcases breadth and depth of research in Crohn’s disease and ulcerative colitis at UEG Week 2023

Written by | 14 Oct 2023

AbbVie will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17. AbbVie… read more.

MHRA (UK) approves Bimzelx for patients with active psoriatic arthritis and adult patients with active axial spondyloarthritis – UCB

Written by | 10 Sep 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for bimekizumab (Bimzelx, UCB) for patients with active psoriatic arthritis and adult patients with active axial… read more.

High BMI elevates risk of several rheumatic diseases – but not equally for everyone

Written by | 2 Jul 2023

A new study by Uppsala University shows that a higher body mass index (BMI) increases the risk of five different rheumatic diseases: rheumatism, osteoarthritis, gout, psoriatic arthritis and… read more.

New research on Otezla in psoriatic arthritis presented at EULAR 2023 – Amgen

Written by | 29 May 2023

Amgen announced new research examining the use of Otezla (apremilast) in psoriatic arthritis, including the Phase IV MOSAIC study and an exploratory analysis of cardiometabolic risk factors, which… read more.

New comprehensive phase III data show first-in-class Tremfya provided durable improvements in measures of psoriatic arthritis through two years – Johnson & Johnson

Written by | 24 Jan 2022

The Janssen Pharmaceutical Companies of Johnson & Johnson announced comprehensive efficacy and safety data from the DISCOVER–2 trial of Tremfya (guselkumab) were published in Arthritis & Rheumatology, representing… read more.

Janssen submits application seeking FDA approval of Stelara for the treatment of pediatric patients with juvenile psoriatic arthritis

Written by | 24 Oct 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA seeking expanded approval of Stelara (ustekinumab) to… read more.

AbbVie announces extension of review for supplemental NDA of upadacitinib to treat psoriatic arthritis

Written by | 26 Mar 2021

AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adult patients with active psoriatic… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.